Teva Pharmaceutical Industries Limited (TEV) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Teva Pharmaceutical Industries Limited (TEV) has a cash flow conversion efficiency ratio of -0.005x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-40.00 Million ≈ $-46.76 Million USD) by net assets (€8.23 Billion ≈ $9.62 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Teva Pharmaceutical Industries Limited (TEV) balance sheet quality index to measure how much of total assets are equity-financed.
Teva Pharmaceutical Industries Limited - Cash Flow Conversion Efficiency Trend (2015–2025)
This chart illustrates how Teva Pharmaceutical Industries Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Teva Pharmaceutical Industries Limited cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Teva Pharmaceutical Industries Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Teva Pharmaceutical Industries Limited ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Trip.com Group Ltd ADR
NASDAQ:TCOM
|
0.014x |
|
Cez A.S.
PR:CEZ
|
0.072x |
|
Advanced Info Service Public Company Limited
BK:ADVANC
|
0.311x |
|
Telefonaktiebolaget LM Ericsson B ADR
NASDAQ:ERIC
|
0.075x |
|
Wanhua Chemical Group Co Ltd
SHG:600309
|
0.057x |
|
SSE PLC ADR LS-50 1
F:SCTA
|
N/A |
|
United Microelectronics Corporation
F:UMCB
|
0.054x |
|
Vodafone Group Plc
MX:VODN
|
0.108x |
Annual Cash Flow Conversion Efficiency for Teva Pharmaceutical Industries Limited (2015–2025)
The table below shows the annual cash flow conversion efficiency of Teva Pharmaceutical Industries Limited from 2015 to 2025. For the full company profile with market capitalisation and key ratios, see TEV market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €7.91 Billion ≈ $9.25 Billion |
€1.65 Billion ≈ $1.93 Billion |
0.208x | -4.42% |
| 2024-12-31 | €5.72 Billion ≈ $6.69 Billion |
€1.25 Billion ≈ $1.46 Billion |
0.218x | +53.11% |
| 2023-12-31 | €8.13 Billion ≈ $9.50 Billion |
€1.16 Billion ≈ $1.35 Billion |
0.142x | -22.17% |
| 2022-12-31 | €8.69 Billion ≈ $10.16 Billion |
€1.59 Billion ≈ $1.86 Billion |
0.183x | +157.78% |
| 2021-12-31 | €11.24 Billion ≈ $13.15 Billion |
€798.00 Million ≈ $932.95 Million |
0.071x | -35.44% |
| 2020-12-31 | €11.06 Billion ≈ $12.93 Billion |
€1.22 Billion ≈ $1.42 Billion |
0.110x | +121.39% |
| 2019-12-31 | €15.06 Billion ≈ $17.61 Billion |
€748.00 Million ≈ $874.49 Million |
0.050x | -67.94% |
| 2018-12-31 | €15.79 Billion ≈ $18.46 Billion |
€2.45 Billion ≈ $2.86 Billion |
0.155x | +30.47% |
| 2017-12-31 | €18.75 Billion ≈ $21.91 Billion |
€2.23 Billion ≈ $2.60 Billion |
0.119x | +6.78% |
| 2016-12-31 | €34.99 Billion ≈ $40.91 Billion |
€3.89 Billion ≈ $4.55 Billion |
0.111x | -39.97% |
| 2015-12-31 | €29.93 Billion ≈ $34.99 Billion |
€5.54 Billion ≈ $6.48 Billion |
0.185x | -- |
About Teva Pharmaceutical Industries Limited
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-po… Read more